drugset / Trial / NCT06588686
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Phase 2
Active not recruiting
378 enrolled
Vicore Pharma AB
Population Services International · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Timeline
- Start
- 2024-12-09
- Primary completion
- 2027-05
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buloxibutid | Small molecule | 50 mg | Oral |
| Subject | Buloxibutid | Small molecule | 100 mg | Oral |